Esperion Therapeutics, Inc. (ESPR) Can’t Be More Risky. The Stock Formed a Ascending Triangle

March 19, 2018 - By Louis Casey

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.45, from 1.22 in 2017Q2. It is positive, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported.
Morgan Stanley has 33,212 shares for 0% of their portfolio. Bankshares Of New York Mellon Corporation invested in 115,372 shares or 0% of the stock. Jane Street Group Inc Ltd Liability has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). California State Teachers Retirement System stated it has 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Citigroup stated it has 28,552 shares. Northern Trust Corp holds 0.01% or 577,917 shares in its portfolio. Parametric Portfolio Associate Ltd invested in 0% or 49,335 shares. State Street, a Massachusetts-based fund reported 1.26M shares. Wells Fargo And Mn owns 14,519 shares for 0% of their portfolio. Schwab Charles Inv Mgmt Inc accumulated 91,843 shares or 0% of the stock. 33,975 were reported by Emory University. Victory Capital Mgmt accumulated 282 shares. Tiaa Cref Inv Mgmt Ltd has 42,254 shares for 0% of their portfolio. Pentwater Capital L P stated it has 0.96% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Macquarie Gru, Australia-based fund reported 23,329 shares.

The stock of Esperion Therapeutics, Inc. (ESPR) formed an ascending triangle with $67.77 target or 8.00 % below today’s $73.67 share price. The 7 months triangle pattern indicates high risk for the $1.95B company. If the $67.77 price target is reached, the company will be worth $156.16M less.
The ascending triangle is a questionable performer despite its reputation as a reliable chart pattern. The ascending triangle has break even failure rate for up and down breakouts of 13% and 11%, respectively. The average rise and decline is 35% and 19%. The throwback or so called pullback rates are: 57% and 49%. The stocks meeting their targets is high for this type of breakout: 75% and 68% percent.

The stock decreased 3.74% or $2.865 during the last trading session, reaching $73.665. About 272,363 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since March 19, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on May, 3. They expect $-1.45 earnings per share, up 19.44 % or $0.35 from last year’s $-1.8 per share. After $-1.44 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.69 % negative EPS growth.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 58 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by Needham on Thursday, December 14. The rating was maintained by Cowen & Co with “Buy” on Wednesday, March 7. The firm earned “Buy” rating on Monday, January 15 by Stifel Nicolaus. On Tuesday, September 29 the stock rating was maintained by Chardan Capital Markets with “Sell”. Lake Street initiated it with “Buy” rating and $94 target in Monday, October 26 report. The rating was maintained by Stifel Nicolaus on Monday, June 26 with “Buy”. The rating was upgraded by Needham on Monday, August 10 to “Buy”. The stock has “Underperform” rating by Credit Suisse on Wednesday, June 29. The rating was upgraded by Credit Suisse to “Neutral” on Monday, March 20. The firm has “Buy” rating by Needham given on Thursday, June 30.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.